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Introduction
Protein misfolding and aggregation play a key role in 
many neurodegenerative disorders. In Alzheimer’s disease 
(AD), β-amyloid (Aβ) and tau proteins accumulate, form-
ing the two hallmark pathologies of senile plaques and 
neurofi brillary tangles [1,2]. In the Lewy body spec trum 
of disorders – which includes Parkinson’s disease, 
Parkinson’s disease with dementia (PDD), and dementia 
with Lewy bodies (DLB) – insoluble aggregates of a 
diff erent protein, α-synuclein (α-syn), accumulate in the 
form of Lewy bodies and Lewy neurites [2-4].
Th e pathological identifi cation of Aβ plaques and 
neurofi brillary tangles versus Lewy bodies has historically 
been used to distinguish between AD and the dementing 
forms of Lewy body disease. A large proportion of AD 
patients (>50%), however, exhibit signifi cant Lewy body 
pathology in addition to plaques and tangles [5-8]. Th e 
postmortem identifi cation of these patients is also 
increasing as examination of all three proteins becomes 
more widely employed [8]. Interestingly, this subpopu-
lation of patients – often termed as those with the Lewy 
body variant of Alzheimer’s disease (AD-LBV) – exhibit 
more rapid cognitive decline and shortened survival 
times compared with pure AD cases [9-12]. In addition to 
AD-LBV cases, amyloid plaques have been detected in 
some patients clinically diagnosed with DLB and less 
frequently in cases of PDD [3,4,13-16].
Th ese varying combinations of Aβ, tau, and α-syn that 
occur have led to considerable confusion regarding the 
diagnosis of patients that exhibit all three pathologies. To 
establish a more clearly defi ned set of diagnostic criteria 
for DLB, a consortium of expert neurologists and patho-
lo gists therefore proposed a set of specifi c recommen-
dations [3]. For example, the likelihood of DLB is ‘directly 
related to the severity of Lewy-related pathology, and 
inversely related to the severity of concurrent AD-type 
pathology’ (see Table 3 in [3]). Th ese revised criteria have 
helped to better clinically defi ne DLB and to distinguish 
cases of DLB that occur without concurrent AD 
pathology from AD-LBV patients who exhibit both DLB 
and AD-asso ciated pathologies.
Aβ plaques, neurofi brillary tangles, and Lewy bodies 
do not occur in high enough individual frequency to 
explain their co-existence in AD-LBV brains [17,18]. 
Instead, researchers have hypothesized that Aβ, tau, and 
α-syn might promote the accumulation or aggregation of 
one another [17,18]. Over the last decade a number of 
studies have confi rmed this hypothesis, and experiments 
have begun to unravel the molecular and cellular 
mechanisms by which these proteins interact [19-22].
It is important to point out that Aβ and α-syn 
pathologies do not co-exist in all AD-LBV brain regions 
or in all cases of AD and DLB [3]. Synucleinopathies such 
as multiple system atrophy and axon dystrophies also 
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show no evidence of concurrent Aβ deposition [23,24]. 
Aβ and α-syn thus appear to interact in a disease-specifi c 
and anatomical-specifi c manner. By examining the 
mecha nisms by which these proteins interact we will 
probably enhance our understanding of why Aβ and α-
syn patho logies co-exist in many, but not all, AD patients.
In the present review we shall examine the evidence 
supporting a role for synergistic interactions between Aβ 
and α-syn in the development and progression of AD-LBV. 
We will also discuss putative mechanisms by which Aβ 
and α-syn could interact and infl uence disease progression.
Clinical prevalence of the Lewy body variant of 
Alzheimer’s disease
Between 50 and 60% of AD patients exhibit signifi cant 
amounts of both Aβ and α-syn pathology at autopsy [3,6]. 
Th ese AD-LBV patients often present with a more aggres-
sive form of dementia featuring a higher rate of cognitive 
decline and shortened survival versus pure AD [9,11,12,25]. 
After AD, DLB appears to be the second most common 
form of age-related dementia [3]. Clinically, pure DLB 
patients who lack Aβ pathology often exhibit diff erent 
cognitive defi cits compared with AD or other dementias. 
Th e core diagnostic criteria for DLB include fl uctuating 
cognition and attention, persistent visual halluci nations, 
and spontaneous Parkinsonian symptoms. DLB patients 
may also possess greater defi cits in working memory, atten-
tion, executive function, and visuospatial ability than AD 
patients [3,12]. Pure DLB cases are rela tively rare (~20%), 
however, and Aβ pathology is often also present [3,26,27]. 
In these cases of mixed pathology, clinical diag nosis can be 
more diffi  cult as the cognitive decline more closely 
resembles the cognitive profi le of AD with the addition of 
some of the unique DLB-associated symptoms [25,26].
Interestingly, not all studies have reported such cog ni-
tive diff erences between AD patients, AD-LBV patients, 
and DLB patients, perhaps as a result of varying method-
ology such as not including postmortem α-syn or Aβ 
histochemical assessments [12]. Additionally, given the 
diff ering cognitive profi les of AD, AD-LBV, and DLB, 
direct comparison of cognitive decline and the rate of 
decline can be diffi  cult and dependent on the assessments 
utilized [11,25,26]. PDD patients, who can show very 
similar pathology and symptoms to DLB patients, can 
also sometimes exhibit both Aβ plaques and Lewy bodies. 
Although the onset of dementia in PDD patients is highly 
variable, it appears to be infl uenced by Aβ pathology 
[4,13]. Several disease states that involve α-syn pathology 
can thus also exhibit varying degrees of Aβ pathology.
Synergistic interactions between β-amyloid and 
α-synuclein
Given the intriguing overlap of Aβ and α-syn pathology 
that occurs in these various dementing disorders, 
researchers have begun to examine the interactions 
between these two proteins and pathologies. Both in vitro 
and in vivo experiments have started to identify potential 
mechanisms by which Aβ and α-syn may interact, 
providing critical results that promise to advance our 
understanding of these inter-related neurodegenerative 
diseases.
In vitro examinations
Using cell-free assays, researchers fi rst began to explore 
potential direct interactions between Aβ and α-syn. For 
example, incubation of recombinant human α-synuclein 
(hSYN) with Aβ42 promoted and increased the formation 
of high-molecular-weight hSYN oligomers [19]. Interest-
ingly, while Aβ42 induced α-syn oligomer formation, co-
incubation with the less pathogenic Aβ40 did not. 
Virtually identical results were observed in a cell culture 
model where extracellular Aβ42, but not Aβ40, promoted 
the formation of intracellular α-syn aggregates [19]. 
Expanding upon these results, Aβ40 and Aβ42 were both 
shown to directly interact with α-syn in vitro [20]. How-
ever, α-syn appears to induce a greater structural change 
in Aβ42. While Aβ40 remains soluble in solution following 
α-syn co-incubation, Aβ42 instead forms oligomers and 
insoluble precipitates [20]. Th e implication that α-syn 
may preferentially interact with Aβ42 is important given 
the known toxic and aggregate-prone properties of Aβ42 
relative to other Aβ isoforms [28,29].
Continuing to implicate Aβ42 as a critical component in 
the interactions between Aβ and α-syn is the result that a 
mutation in presenilin 1, which increased Aβ42, also 
enhanced the pathogenic phosphorylation and aggrega-
tion of α-syn in both patients and cells [21]. Th is result 
not only provides further support for the idea that Aβ42 
plays a key role in the aggregation of α-syn, but also 
suggests a possible mechanism; the Aβ42-induced phos-
phory lation of α-syn. In the normal brain, about 4% of α-
syn is phosphorylated at serine 129 (pS129-syn). In 
contrast, up to 90% of α-syn is phosphorylated at this site 
in synucleinopathies such as DLB, suggesting an impor-
tant role in pathogenesis [30,31]. Indeed, phosphorylation 
of α-syn at serine 129 (Ser129) can promote fi bril 
formation in vitro [30]. Aβ42-induced phosphorylation of 
α-syn therefore provides an intriguing mechanism by 
which Aβ may enhance α-syn pathology.
Th ere is considerable in vitro evidence that α-syn can 
also interact with tau, the other major pathological 
protein in AD. Whereas α-syn has been shown to self-
polymerize in vitro [32], tau instead requires cofactors to 
polymerize [33]. Interestingly, α-syn can itself serve as a 
cofactor to promote tau polymerization and both 
proteins co-localize within inclusion bodies [17,18,34]. 
Recent evidence has shown that co-transfection of α-syn 
with tau induces insoluble, cytotoxic, α-syn aggregate 
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formation [34]. Likewise, cellular seeding with α-syn 
fi brils induces the formation of cytotoxic neurofi brillary 
tangle-like inclusions [35]. Extracellular seeding of α-syn 
fi brils can also promote recruitment of soluble α-syn into 
insoluble Lewy body-like inclusion bodies [36].
Transgenic models that combine β-amyloid and 
α-synuclein pathology
Mouse models of overlapping Aβ and α-syn pathology 
lend further support to the theory that Aβ and α-syn 
interact synergistically to create a more severe disease 
course. Double-transgenic mice expressing human amy-
loid precursor protein (APP) and wild-type hSYN develop 
motor defi cits at 6 months compared with 12 months in 
single-transgenic hSYN mice [19]. Th ese human APP/
hSYN mice also develop spatial memory defi cits and 
increased numbers of Lewy body-like inclu sions [19]. 
Th ese double-transgenic mice therefore provide a useful 
model for examining the potential inter actions between 
Aβ and α-syn.
To model all three of the pathologies that co-exist 
within AD-LBV patients, Clinton and colleagues crossed 
3xTg-AD transgenic mice with a mutant α-synuclein trans-
genic line [22]. Th e 3xTg-AD model develops Aβ plaque 
and neurofi brillary tangle pathology via co-expression of 
mutant APP, mutant presenilin-1, and mutant tau. By 
adding a mutant α-syn (A53T) transgene to the mix, this 
model (hereafter referred to as AD-LBV mice) success-
fully recapitulated all three major AD-LBV pathologies 
[22]. Interestingly, AD-LBV mice exhibit accelerated 
cognitive dysfunction versus 3xTg-AD or α-syn lines, 
suggesting that this complex model mimics an important 
feature of AD-LBV. Similar to the single-transgenic α-syn 
mouse, the AD-LBV mice develop Lewy body-like inclu-
sions. However, AD-LBV mice show increased levels of 
insoluble α-syn, pS129-syn, and Lewy body pathology at 
much earlier ages than single-transgenic α-syn mice. Two 
other pathological results of interest are that AD-LBV 
mice develop increased levels of insoluble Aβ42 tau at 
younger ages than 3xTg-AD mice. Although this model 
uses mutant transgenes, the results nevertheless provide 
important additional evidence that Aβ, tau, and α-syn 
can interact synergistically to acceler ate pathogenesis and 
cognitive decline.
While much of the in vivo evidence linking Aβ and α-
syn comes from the use of transgenic mice that express 
mutant genes, the study of these models has yielded 
invaluable additions to our knowledge of neuro degenera-
tive disease [1,18,37]. Importantly, similar results have 
been found in models regardless of whether mutant [22] 
or wild-type [19] α-syn transgenes were utilized. Interest-
ingly, investigations of familial AD presenilin 1, presenilin 2, 
and APP mutation carriers also reveal increased develop-
ment of Lewy body pathology [38-40]. Both mouse 
models and human cases thus suggest that disease-
associated APP and presenilin mutations can enhance 
the pathological accumulation of wild-type α-syn.
Potential mechanisms that link β-amyloid and 
α-synuclein pathology
While the interactions between AΒ and α-syn have been 
well documented, far less is known about the mechanisms 
by which these proteins exert their eff ects on one another. 
Research aimed at elucidating these mechanisms will no 
doubt provide critical knowledge about the progression 
of AD, AD-LBV, DLB, and PDD, and thus may also yield 
new therapeutic targets.
Phosphorylation of α-synuclein and tau
One mechanism that may underlie the eff ects of Aβ on 
α-syn is by indirectly infl uencing the phosphorylation 
state of α-syn. As previously mentioned, Ser129 α-syn 
phosphorylation is a pathogenic change observed in DLB 
and other synucleino pathies, and interactions with Aβ 
and tau can enhance phosphorylation at this residue in 
vitro and in vivo [22,30]. Several kinases have been 
identifi ed that may mediate Ser129 phosphorylation, but 
the most impor tant appear to be casein kinase 2 and 
polo-like kinase 2 (PLK2) [30,41-44]. PLK2 was recently 
shown to phosphorylate α-syn at Ser129 with greater 
effi  ciency than casein kinase 2 [44]. Interestingly, PLK2 
expression is elevated in AD and DLB patient neurons. 
Phos phory lation of Ser129 was also recently detected in 
synaptic-enriched fractions from AD patients [45]. 
Upregulation of PLK2 in AD and DLB could thus 
potentially mediate the increased phos phory lation of α-
syn observed in these patients. Increased phosphorylation 
of Ser129 has in turn been shown to increase the 
propensity of α-syn to form aggregates [30]. In contrast, 
one recent study found that increasing pS129 through 
various mechanisms, including increased PLK2 expres sion, 
did not alter the aggregation state [46]. While the evidence 
is clear that pS129-syn is associated with pathogenic 
changes, further research is needed to clarify the functional 
eff ects of Ser129 phosphorylation and the potential role of 
pS129-syn in Aβ and synuclein interactions.
Th e hyperphosphorylation of tau and its aggregation 
into neurofi brillary tangles and dystrophic neurites 
(Figure 1) is a hallmark of AD. A number of studies have 
shown that Aβ can modulate tau phosphorylation and 
aggregation [47-49]. α-syn can also infl uence tau patho-
logy [50,51]. Th e interactions between α-syn and tau 
appear bidirectional, however, as tau can also induce 
synuclein aggregation and phosphorylation [34]. In fact, 
tau overexpression can induce PLK2 expression, 
providing a potential mechanism for this eff ect [52]. Aβ 
could therefore possibly drive synuclein pathology 
indirectly by fi rst enhancing tau pathogenesis (Figure 2).
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β-amyloid-induced infl ammation
Infl ammation is a critical component of AD [53] and also 
contributes to the pathogenesis of Lewy body disorders 
[54,55]. Although there is currently limited evidence 
connecting Aβ-induced infl ammation with α-syn aggre ga-
tion, we speculate that the eff ects of Aβ on infl amma tory 
processes could indirectly drive the phosphorylation and 
aggregation of α-syn. A growing body of evidence suggests 
that Aβ can indeed infl uence tau pathology via this kind of 
mechanism. For example, Aβ-induced release of pro-
infl am matory cytokines can in turn activate kinases such 
as cyclin-dependent kinase 5 that promote tau phos phory-
lation [37,56,57]. Interestingly, cyclin-depen dent kinase 5 
has also been implicated in Lewy body formation  – this 
same kinase may therefore infl uence α-syn aggregation 
[58]. In further support of this hypo the sis, age-related 
changes in microglial activation and cyto kine release can 
enhance nitric oxide production, increas ing α-syn 
nitration [59]. Nitration and oxidation of α-syn can in turn 
accelerate α-syn aggre gation [60]. Th e relationship 
between α-syn and infl am mation appears to be reciprocal, 
as α-syn can itself can drive astrocytic and microglia 
activation [61,62]. Notably, one recent report showed that 
tau overexpression can also drive infl ammation and 
enhance α-syn accumulation and phosphorylation [52].
Clearly a great deal more work is needed to determine 
whether infl ammation truly infl uences the interactions 
between Aβ and α-syn. However, infl ammatory-mediated 
changes in cytokine expression and kinase activation 
probably infl uence α-syn in much the same way as they 
modulate tau.
Impaired protein degradation
Another common mechanism thought to underlie many 
neurodegenerative disorders is dysfunction in protein 
clearance mechanisms. Indeed, impairments in both the 
ubiquitin–proteasome system and the autophagy–
lysosome pathway occur in AD and Parkinson’s disease, 
and both pathways are important in Aβ and α-syn 
degradation [63-67]. Soluble oligomeric Aβ, in addition 
to aggregated α-syn, impairs the normal function of the 
proteasome [63,68]. Th e ubiquitin–proteasome system is 
also critical in the degradation of tau, and the E3 ligase 
(C-terminus Hsp70 interacting protein) targets both tau 
Figure 1. α-synuclein and tau immunoreactive dystrophic neurites surround β-amyloid plaques. Top panels: β-amyloid (Aβ) plaque (green) 
is surrounded by α-synuclein immunoreactive neurites (red) in the neocortex of a Lewy body variant of Alzheimer’s disease patient. Bottom panels: 
Both tau immunoreactive dystrophic neurites (green) and α-synuclein (red) are detected in association with a neuritic plaque.
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and α-syn for degradation [69-71]. Interestingly, protea-
somal impair ment caused by one pathogenic protein may 
in turn reduce degradation of other pathogenic proteins. 
For example, Aβ-induced proteasome dysfunction 
increases the accumulation of tau [64,68].
Both α-syn and Aβ are also degraded by autophagy. 
Pathogenic interactions between α-syn and Aβ could 
therefore infl uence the function of this critical pathway. 
For example, a subset of neurons with increased levels of 
α-syn has been shown to recruit the autophagy pathway 
to compensate for impaired ubiquitin–proteasome system 
function. An increased burden on lysosomal degradation 
could thus drive dysfunction in vulnerable neuronal 
populations [63,66]. Uptake of Aβ42 was also shown to 
induce lyso somal leakage, providing another possible 
mechanism for both direct and indirect interactions 
between Aβ42 and α-syn [19,63]. Interestingly, activation 
of autophagy by over expression of Beclin-1 can reduce 
Figure 2. Potential mechanisms linking β-amyloid and α-synuclein pathology. Studies support several putative mechanisms by which 
β-amyloid (Aβ) and α-synuclein (α-syn) may interact to enhanced pathology and cognitive decline. Such mechanisms include (left to right): chronic 
infl ammation and microglial activation induced by both Aβ and α-syn; direct interactions and hybrid oligomerization of Aβ and α-syn; Aβ-induced 
kinase activation and α-syn phosphorylation; impairment of proteasome and autophagy degradation pathways; and Aβ-induced phosphorylation 
of tau leading to tau-mediated enhancement of α-syn aggregation. CK-2, casein kinase 2; PLK-2, polo-like kinase 2; PHF, paired helical fi laments; 
NFT, neurofi brillary tangle; p-Tau, phosphorylated tau; pS129, phosphorylated at serine 129; p-syn, phosphorylated α-synuclein; UPS, ubiquitin–
proteasome system.
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not only Aβ levels but also α-syn pathology [72,73]. 
Impairments in auto phagy could therefore simul ta-
neously drive the accumu lation of both Aβ and α-syn.
Finally, there is the possibility of disruption of cyto plas-
mic protease activity. For example, the serine protease 
neurosin (kallikrein-6) has been shown to degrade α-syn 
and to prevent its polymerization [63]. Intriguingly, 
neurosin is dysregulated in Parkinson’s disease and 
decreased in the brains of AD patients, providing another 
possible mechanism by which impaired protein clearance 
could drive synuclein pathology [63].
Impaired protein degradation clearly plays a substantial 
role in many neurodegenerative disorders. Th e combined 
actions of Aβ and α-syn on the ubiquitin–proteasome 
system and autophagy–lysosome systems provide a 
poten tial mechanism to explain the acceleration of patho-
logy and cognitive decline in patients with overlapping 
pathologies. Dysfunction in the lysosomal system may 
also facilitate the direct interaction between Aβ and α-
syn in neuronal subpopulations where Aβ and α-syn co-
exist [19].
Direct interactions between β-amyloid, α-synuclein, and tau
Aβ and α-syn do not normally exist in the same sub-
cellular compartment in healthy cells, thus limiting their 
potential for direct interaction [19]. In pathological 
states, however, the localization of many proteins includ-
ing Aβ and α-syn can be altered. For example, Aβ and α-
syn have both been detected within mitochondria 
[74,75]. Likewise, both proteins can accumulate within 
lysosomes and autophagasomes [76,77]. Direct inter-
actions between these proteins could thus potentially 
occur within damaged or diseased cells. To date, most of 
the evidence supporting direct inter actions between Aβ 
and α-syn comes from in vitro experiments. For example, 
cell-free studies show that α-syn can promote confor ma-
tional changes in Aβ that are detected by NMR spectro-
scopy [20]. Aβ and α-syn can also form complexes and 
can co-immunoprecipitate from AD-LBV patient brains 
and transgenic models, providing some in vivo evidence 
for direct interactions [78]. Th is same study provided 
evidence that these two proteins can form hybrid pore-
like oligomers that increase calcium infl ux. Tau can also 
enhance α-syn aggregation and toxicity [34], and both 
proteins can co-localize within AD-LBV patient neurons, 
dystrophic neurites, and Lewy bodies [17,18,79]. If direct 
interactions between Aβ and α-syn do indeed play a role 
in AD-LBV pathogenesis, it will be important to under-
stand why these interactions occur only in some patients 
and brain regions but not in others.
Conclusions
Th e co-existence of Aβ and α-syn pathologies in 
dementia patients clearly does not simply represent two 
concurrent yet independent disease states. Evidence 
suggests instead that Aβ and α-syn may interact 
synergistically to enhance each others’ aggregation and 
accelerate cognitive decline. Th e mechanisms by which 
these two aggregation-prone proteins interact remain 
unclear. However, growing evidence suggests that Aβ 
may infl uence α-syn pathology by modulating protein 
clearance, driving infl ammation, activating kinases, or 
directly altering α-syn aggregation. While a great deal of 
work is needed to confi rm and clarify these putative 
mechanisms, the prevalence of combined AD and LB 
disease clearly justifi es the need.
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